Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

This invention discloses a type of 1,8-bis(Schiff base)-p-menthane derivatives as well as their preparation method and applications. The reaction of 1,8-diamino-p-menthane with a substituted benzaldehyde was carried out in a polar organic solvent at 0 C.-75 C. for 1-48 h. After the completion of the reaction, part of the solvent was distilled off to perform recrystallization to get a 1,8-bis(Schiff base)-p-menthane derivative, whose pre-emergence herbicidal activity against ryegrass was determined by using the Petri dish seed germination method. The 1,8-bis(Schiff base)-p-menthane derivatives, obtained with this method in high yield and mild reaction conditions, have a good inhibitory effect on the growth of annual ryegrass, and low toxicity.

This invention discloses a type of 1,8-bis(Schiff base)-p-menthane derivatives as well as their preparation method and applications. The reaction of 1,8-diamino-p-menthane with a substituted benzaldehyde was carried out in a polar organic solvent at 0 C.-75 C. for 1-48 h. After the completion of the reaction, part of the solvent was distilled off to perform recrystallization to get a 1,8-bis(Schiff base)-p-menthane derivative, whose pre-emergence herbicidal activity against ryegrass was determined by using the Petri dish seed germination method. The 1,8-bis(Schiff base)-p-menthane derivatives, obtained with this method in high yield and mild reaction conditions, have a good inhibitory effect on the growth of annual ryegrass, and low toxicity.

The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR and inhibitors (antagonists) of sEH. The invention also provides methods for treating subjects suffering from diseases associated with FXR and sEH, such as metabolic disorders, in particular non-alcoholic fatty liver or nonalcoholic steatohepatitis (NASH).

This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

A resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol M diphthalonitrile ether resin. Another resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol T diphthalonitrile ether resin. The resin blends prior to cure have more favorable processing and curing properties compared to the resorcinol diphthalonitrile resin alone, enabling greater ease in manufacturing.

A resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol M diphthalonitrile ether resin. Another resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol T diphthalonitrile ether resin. The resin blends prior to cure have more favorable processing and curing properties compared to the resorcinol diphthalonitrile resin alone, enabling greater ease in manufacturing.

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).